Calistoga Pharmaceuticals

Transforming the treatment of hematologic malignancies through innovative and targeted therapeutics

Calistoga was founded in 2006 to develop the first selective inhibitor of PI3K-delta, a critical signaling molecule for many types of hematologic cancers. Calistoga's outstanding team brought the company's lead asset (then called CAL-101) into clinical studies and immediately achieved remarkable early activity in patients with chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). On the basis of this clinical activity, Gilead acquired Calistoga in 2011. Following futher development (and Breakthrough Therapy designation from the FDA), Gilead achieved both FDA and EU approval in 2014 for CAL-101 (as brand name Zydelig) to treat CLL, FL, and small lymphocytic lymphoma (SLL, US-only).

Status

Acquired by Gilead Sciences in 2011

Year of Investment

2006

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Seattle, Washington